Advertisement
Advertisement
U.S. markets close in 3 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ocumension Therapeutics (1477.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
10.440-0.160 (-1.51%)
At close: 04:08PM HKT
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in HKD

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 5/14/2022
Current
Market Cap (intraday)
6.55B
Enterprise Value
4.52B
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
90.94
Price/Book (mrq)
1.80
Enterprise Value/Revenue
80.53
Enterprise Value/EBITDA
-18.42

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-49.88%
S&P500 52-Week Change 3-5.66%
52 Week High 332.050
52 Week Low 37.970
50-Day Moving Average 39.424
200-Day Moving Average 315.068

Share Statistics

Avg Vol (3 month) 3475.63k
Avg Vol (10 day) 3290.45k
Shares Outstanding 5666.74M
Implied Shares Outstanding 6N/A
Float 8245.67M
% Held by Insiders 139.15%
% Held by Institutions 132.72%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in CNY.

Fiscal Year

Fiscal Year Ends Dec 31, 2021
Most Recent Quarter (mrq)Dec 31, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-687.36%

Management Effectiveness

Return on Assets (ttm)-8.13%
Return on Equity (ttm)-9.27%

Income Statement

Revenue (ttm)56.15M
Revenue Per Share (ttm)0.09
Quarterly Revenue Growth (yoy)217.10%
Gross Profit (ttm)36.94M
EBITDA -382.82M
Net Income Avi to Common (ttm)-259.99M
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.79B
Total Cash Per Share (mrq)2.89
Total Debt (mrq)11.21M
Total Debt/Equity (mrq)0.36
Current Ratio (mrq)8.50
Book Value Per Share (mrq)5.03

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A
Advertisement
Advertisement